Azacitidine

Azacitidine
Product Description

Azacitidine is a cytotoxic hypomethylating chemical analogue of cytidine used in the treatment of myelodysplastic syndromes. Azacitidine EVER Pharma is available in both the standard 100 mg vial size and a new 150 mg vial size aligned to the most common patient doses to minimize waste and maximize preparation efficiency. Currently registered in most EU countries with further registrations in progress or planned.            

Sales markets: Europe – EU countries; Europe – non EU (e.g. UK, Russia, ex-CIS countries)

EVER Pharma

  • AT
  • 2015
    On CPhI since
Company types
CMO/CDMO
Contract Service
Manufacturer/Innovator

EVER Pharma

  • AT
  • 2015
    On CPhI since
Company types
CMO/CDMO
Contract Service
Manufacturer/Innovator

More Products from EVER Pharma

  • OXYTOCIN

    Product OXYTOCIN

    Oxytocin is a drug that belongs to the group of medicines called oxytocins and it is identical with oxytocin, a hormone released by the pituitary gland, which has an effect on the muscles of the uterus (womb). Oxytocin EVER Pharma is a generic version of Syntocinon® (Novartis) and indicated for the induction of labour for medical reasons; stimulation of labour in hypotonic uterine inertia; during caesarean section, following delivery of the child; prevention and treatment of postpartum uterine atony and haemorrhage. Early stages of pregnancy as an adjunctive therapy for the management of incomplete, inevitable, or missed abortion. Currently registered in the UK and France with further registrations in progress or planned.
  • CEREBROLYSIN®

    Product CEREBROLYSIN®

    EVER Neuro Pharma GmbH offers a wide range of products which includes CEREBROLYSIN®. It is a biotechnologically prepared peptide that stimulates neurotrophic regulation in the central nervous system. It is used worldwide for treatment of ischemic and hemorrhagic stroke, traumatic brain injuries, to treat different forms of dementia (vascular dementia, Alzheimer's disease) and cognitive disorders and to prevent cognitive decline after brain injuries.contact us for more information.
  • DACEPTON®

    Product DACEPTON®

    EVER Neuro Pharma GmbH offers a wide range of products which includes DACEPTON®. It is used for treatment of movement disorders (“on-off” phenomena) in patients with Parkinson's disease and who cannot be effectively treated using oral anti-Parkinson medicine.contact us for more information.
  • TACHYBEN®

    Product TACHYBEN®

    EVER Neuro Pharma GmbH offers a wide range of products which includes TACHYBEN®. It is used for intravenous treatment of hypertensive emergencies (e.g. critical rise in blood pressure), in cases of severe and very severe forms of hypertensive disease as well as in cases of hypertension resistant to treatment.contact us for more information.
  • ATOSIBAN

    Product ATOSIBAN

    Atosiban is an inhibitor of the hormones oxytocin and vasopressin. It is used as an intravenous medication as a labour repressant (tocolytic) to halt premature labour. Atosiban EVER is indicated1 to delay imminent pre-term birth in pregnant adult women with a gestational age from 24 until 33 completed weeks. Available as a convenient ready to use fixed dose (bolus injection) and fixed volumes concentrate for dilution (high dose/low dose infusions). Currently registered in 15 European countries, further registrations are in progress or planned globally. The product is indicated to delay imminent pre-term birth in pregnant adult women with: regular uterine contractions of at least 30 seconds duration at a rate of ≥ 4 per 30 minutes, a cervical dilation of 1 to 3 cm (0-3 for nulliparas) and effacement of ≥ 50%, a gestational age from 24 until 33 completed weeks, a normal foetal heart rate Ready to use product – either for immediate use or dilution for infusion. No reconstitution from powder required.Available in vials – safer and more convenient than ampoulesAvailable in 3 presentations – to cover loading, and high dose/low dose infusion administration stages
  • TERLIPRESSIN

    Product TERLIPRESSIN

    Terlipressin EVER Pharma is indicated for the treatment of bleeding oesophageal varices and Hepato-renal syndrome type 1. NICE (UK) guidelines are to offer terlipressin to patients with suspected variceal bleeding at presentation and the WGO recommend it as the first choice for pharmacological therapy to control bleeding and mortality. Terlipressin EVER Pharma was developed to offer a more convenient and safer to use product than the originator Glypressin®. Available as a ready to use solution in a vial, there is no need to either reconstitute the product with solvent or break open ampoules. Both initial and maintenance dose ranges are conveniently and economically covered by providing a 10mL vial in addition to the current 5ml vial. Currently registered in 10 European countries with further registrations in progress or planned globally. Ready to use product – for immediate use without reconstitutionAvailable in vials – safer and more convenient than ampoules5ml and new 10ml presentation – covering initial and maintenance dose rangesAdditional indication – for Hepato-renal syndrome type 1
  • Fulvestrant

    Product Fulvestrant

    Fulvestrant EVER Pharma is indicated as monotherapy for the treatment of estrogen receptor positive, locally advanced or metastatic breast cancer in postmenopausal women: • not previously treated with endocrine therapy  • or with disease relapse on or after adjuvant antiestrogen therapy, or disease progression on antiestrogen therapy In combination with palbociclib for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in women who have received prior endocrine therapy
  • Cabazitaxel

    Product Cabazitaxel

    Cabazitaxel is a third-generation antineoplastic taxane and was the first therapy to show a survival benefit for the treatment of patients with docetaxel-refractory mCRPC. Cabazitaxel EVER Pharma is provided as a single vial, ready to dilute formulation and is available in 3 vial sizes covering the common range of patient specific doses for economy and convenience. All presentations are multidose vials with 28 days stability after first opening. Currently registered in most EU countries and AU with further registrations in progress or planned. 

    Sales markets: Europe – EU countries; Europe – non EU (e.g. UK, Russia, ex-CIS countries)
  • Dexmedetomidine

    Product Dexmedetomidine

    The first Dexmedetomidine in Europe indicated for both ICU and procedural sedation Dexmedetomidine is a highly selective alpha-2 adrenergic receptor notable for its ability to provide sedation without the risk of respiratory depression Dexmedetomidine EVER Pharma is indicated for:
    • Sedation of non-intubated adult patients prior to and/or during diag-nostic or surgical procedures requiring sedation, i.e. procedural/awake sedation.
    • Sedation of adult ICU (Intensive Care Unit) patients requiring sedation level not deeper than arousal in response to verbal stimulation corres-ponding to Richmond Agitation-Sedation Scale (RASS) 0 to -3
  • Pemetrexed Vial

    Product Pemetrexed Vial

    Pemetrexed: Pemetrexed is an antineoplastic chemotherapy drug. It is used in the treatment of malignant mesothelioma and locally advanced or metastatic nonsquamous non-small cell lung cancer. Pemetrexed EVER Pharma is provided as a ready to dilute liquid formulation that can be stored at room temperature and is available in 3 vial sizes for economy and convenience. The patient dose is stable for 28 days at 2-8°C and 7 days at 20-30°C providing greater working flexibility and less wasted product. Currently registered in most EU countries with further registrations in progress or planned. 

    Sales markets: Europe – EU countries; Europe – non EU (e.g. UK, Russia, ex-CIS countries)

EVER Pharma resources

Recommended products